O-去甲基凡德他尼 | 910298-60-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: O-去甲基凡德他尼
• 中文别名: 邻去甲基凡德他尼；凡德他尼杂质
• 英文名称: 4-((4-bromo-2-fluorophenyl)amino)-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-6-ol
• 英文别名: O-Demethyl Vandetanib；4-(4-bromo-2-fluoroanilino)-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-6-ol
• CAS: 910298-60-1
• 化学式: C₂₁H₂₂BrFN₄O₂
• 分子量: 461.334
• InChiKey: XFRILWHQVZXWIN-UHFFFAOYSA-N

物化性质

• 熔点：
  223-225 °C
• 沸点：
  554.0±50.0 °C(Predicted)
• 密度：
  1.476±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.5
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  O-去甲基凡德他尼 、 [11C]methyl triflate 在 sodium hydroxide 作用下， 以 乙腈 为溶剂， 反应 0.05h， 生成 N-(4-bromo-2-fluorophenyl)-6-[11C]methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
  参考文献：
  名称：

  Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer

  摘要：

  Vandetanib (ZD6474) and its chlorine analogue chloro-Vandetanib are potent and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors with low nanomolar IC50 values. [C-11]Vandetanib and [C-11]chloro-Vandetanib, new potential PET agents for imaging of VEGFR in cancer, were first designed, synthesized and labeled at nitrogen and oxygen positions from their corresponding N- and O-des-methylated precursors, in 40-50% decay corrected radiochemical yield and 370-555 GBq/mu mol specific activity at end of bombardment (EOB). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.049
• 作为产物：
  描述：

  凡德他尼 在 吡啶盐酸盐 作用下， 反应 1.33h， 以17%的产率得到O-去甲基凡德他尼
  参考文献：
  名称：

  Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer

  摘要：

  Vandetanib (ZD6474) and its chlorine analogue chloro-Vandetanib are potent and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors with low nanomolar IC50 values. [C-11]Vandetanib and [C-11]chloro-Vandetanib, new potential PET agents for imaging of VEGFR in cancer, were first designed, synthesized and labeled at nitrogen and oxygen positions from their corresponding N- and O-des-methylated precursors, in 40-50% decay corrected radiochemical yield and 370-555 GBq/mu mol specific activity at end of bombardment (EOB). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.049

文献信息

• [EN] SUBSTITUTED QUINAZOLINE INHIBITORS OF GROWTH FACTOR RECEPTOR TYROSINE KINASES<br/>[FR] INHIBITEURS DE TYROSINE KINASES DE RÉCEPTEUR DE FACTEUR DE CROISSANCE DE TYPE QUINAZOLINE SUBSTITUÉE
  申请人：AUSPEK PHARMACEUTICALS INC

  公开号：WO2010028254A2

  公开（公告）日：2010-03-11

  The present invention relates to new substituted quinazoline inhibitors of vascular endothelial growth factor receptor tyrosine kinase, epidermal growth factor receptor tyrosine kinase, and/or rearranged during transfection tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.

  本发明涉及新的取代喹唑啉血管内皮生长因子受体酪氨酸激酶、表皮生长因子受体酪氨酸激酶和/或转录重排期间酪氨酸激酶抑制剂、其制药组合物以及使用方法。
• Spirocyclic degronimers for target protein degradation
  申请人：C4 Therapeutics, Inc.

  公开号：US10660968B2

  公开（公告）日：2020-05-26

  This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

  本发明提供了具有螺环 E3 泛素连接酶靶向基团（Degrons）的化合物，这些化合物可单独使用，也可与用于体内降解的蛋白质的靶向配体连接，本发明还提供了其使用方法和组合物及其制备方法。
• C3-carbon linked glutarimide degronimers for target protein degradation
  申请人：C4 Therapeutics, Inc.

  公开号：US10849982B2

  公开（公告）日：2020-12-01

  This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

  本发明提供了具有碳连接的 E3 泛素连接酶靶向分子（Degronimers）的 Degronimers（Degronons），这些 Degronimers 可与用于体内降解的蛋白质的靶向配体连接，本发明还提供了其使用方法和组合物及其制备方法。
• Heterocyclic degronimers for target protein degradation
  申请人：C4 Therapeutics, Inc.

  公开号：US10905768B1

  公开（公告）日：2021-02-02

  This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

  本发明提供了能与 E3 泛素连接酶（通常是通过脑龙）（"Degrons"）结合的杂环化合物，这些杂环化合物可用于治疗目的或与选定靶蛋白的靶向配体相连接，并提供了其使用方法和组合物及其制备方法。
• SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
  申请人：C4 Therapeutics, Inc.

  公开号：US20210106688A1

  公开（公告）日：2021-04-15

  This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.